The GLI3 Knockout HeLa Polyclonal Cells consist of a CRISPR/Cas9-edited polyclonal population derived from HeLa human cervical adenocarcinoma cells, engineered for GLI3 gene disruption. This heterogeneous cell pool eliminates full-length GLI3 protein expression, offering a loss-of-function model to interrogate Hedgehog pathway-dependent mechanisms. The polyclonal format ensures genetic diversity while abolishing GLI3-mediated transcriptional regulation, making it a versatile tool for functional genomics in an epithelial cancer background.
HeLa cells are an immortalized epithelial line from an HPV-18 positive cervical adenocarcinoma, widely employed as a model for human epithelial cancers. Their well-characterized signaling pathways, rapid growth, and genetic tractability make them ideal for investigating oncogenic processes and drug sensitivity. The HPV-driven transformation background provides a physiologically relevant context for studying GLI3 functions, particularly where Hedgehog signaling intersects with viral oncogenesis and epithelial tumor biology.
GLI3 encodes a zinc-finger transcription factor that is a key effector of the Hedgehog pathway. In the absence of SHH, PTCH1 inhibits SMO, leading to proteolytic processing of GLI3 into a repressor form (GLI3R) via PKA, CK1, and GSK3??. SHH binding relieves inhibition, allowing full-length activator GLI3 (GLI3A) to accumulate in the nucleus and activate targets such as GLI1, CCND1, MYCN, and BCL2. GLI3 functions are modulated by interactions with SUFU, SPOP, and CBP/p300, and it engages in crosstalk with Wnt signaling through ??-catenin. Knockout of GLI3 abrogates both repressor and activator activities, disrupting downstream gene programs.
In HeLa cells, GLI3 knockout disrupts the dual repressor/activator dynamics, offering a clean background to dissect Hedgehog pathway contributions to cervical adenocarcinoma cell proliferation and survival. Since HeLa cells express components of the Hedgehog pathway, loss of GLI3 may impair proliferation, alter differentiation markers, and sensitize cells to pathway inhibitors. This model is therefore valuable for deciphering GLI3-specific roles in oncogenic signaling and for evaluating therapeutic strategies targeting Hedgehog-driven processes in HPV-positive cancers.
These polyclonal knockout cells are suitable for diverse experimental applications. Hedgehog pathway activity can be monitored via luciferase reporters and RT-qPCR of target genes. Western blotting detects GLI3 isoforms, while proliferation assays (MTT, BrdU) assess growth effects. RNA-seq and ChIP-qPCR enable transcriptome-wide and binding-site analyses. The cells also support drug screening for Hedgehog inhibitors. For further information, please contact Ascent Research.
